Sign Up to like & get
recommendations!
0
Published in 2025 at "Journal of Crohn's and Colitis"
DOI: 10.1093/ecco-jcc/jjae190.1191
Abstract: Filgotinib (FIL), a once-daily, oral Janus kinase 1 preferential inhibitor, was approved for the treatment of Ulcerative Colitis (UC) following the phase 2b/3, randomized SELECTION clinical trial.1 Real-world data on the effectiveness and safety of…
read more here.
Keywords:
effectiveness safety;
fil;
real world;
fil fil ... See more keywords